Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled date : 2021 - 10 - 19 save search
Global IoT-Enabled Industrial Wearables Market to Reach $3.5 Billion by 2026
Published: 2021-10-19 (Crawled : 15:00) - prnewswire.com
SEKEY | $8.91 5.32% -1.89% 0
|
Manufacturing
|
| O: 2.5%
H: 0.0%
C: -1.83%
VUZI P 14500 | $1.35 11.57% 10.37% 5.2K
|
Electronic Technology
|
| O: 0.61%
H: 4.54%
C: 3.64%
KOPN | $1.29 5.74% 6.51% 24K
|
Electronic Technology
|
| O: 1.06%
H: 2.95%
C: 2.11%
iot trial
First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis
Published: 2021-10-19 (Crawled : 15:00) - biospace.com/
FWBI | $2.91 2.2K
|
Manufacturing
|
| O: 6.23%
H: 1.38%
C: -3.1%
fda clearance treatment fda phase 2 biopharma application trial clearance phase 2b
With Market Size Valued at $1.3 Billion by 2026, it`s a Healthy Outlook for the Global Industrial Communication Gateways Market
Published: 2021-10-19 (Crawled : 14:15) - prnewswire.com
GIC | $40.37 -0.37% 0.0% 0
|
Retail Trade
|
| O: 0.65%
H: 2.29%
C: 1.97%
EMR | $109.21 0.53% 91K
|
Producer Manufacturing
|
| O: 0.7%
H: 0.15%
C: -0.02%
CSCO | News | $48.24 0.21% 430K
|
Technology Services
|
| O: 0.18%
H: 0.89%
C: 0.81%
communication trial
Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis
Published: 2021-10-19 (Crawled : 14:00) - biospace.com/
GRTX | $0.1908 3.7% 3.61% 19K
|
Health Technology
|
| O: -72.03%
H: 22.71%
C: 8.7%
therapy results phase 3 iot trial oral mucositis avasopasem roman trial
Lilly's Longest Diabetes Drug Trial Lowers A1C and Increases Weight Loss
Published: 2021-10-19 (Crawled : 14:00) - biospace.com/
LLY | News | $731.33 0.69% 0.73% 12K
|
Health Technology
|
| O: 0.03%
H: 1.46%
C: 1.36%
weight loss diabetes drug trial
Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
Published: 2021-10-19 (Crawled : 14:00) - biospace.com/
AVIR | $3.67 -1.34% -1.09% 0
|
Health Technology
|
| O: -72.41%
H: 48.48%
C: 23.39%
at-527 phase 2 results topline trial
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
Published: 2021-10-19 (Crawled : 13:15) - nantkwest.com
IBRX | $4.94 -6.26% 10.83% 4.5M
|
Manufacturing
|
| O: 0.9%
H: 2.89%
C: 1.78%
disease bladder cancer cancer trial bladder
Avadel Presents New Data Supporting Clinical Benefit with Once-at-Bedtime FT218 and Preference for Once-Nightly Dosing in Patients with Narcolepsy at CHEST 2021
Published: 2021-10-19 (Crawled : 13:15) - biospace.com/
AVDL | $17.3 -0.17% 0.06% 2
|
Health Technology
|
| O: 3.03%
H: 1.2%
C: -2.82%
narcolepsy ft218
Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Published: 2021-10-19 (Crawled : 13:00) - prnewswire.com
MBRX | $4.3 -7.53% -4.49% 0
|
Health Technology
|
| O: 0.37%
H: 3.72%
C: 2.23%
covid treatment phase 1 trial phase 1b
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2021-10-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.35 4.44% 3.43% 0
|
Health Technology
|
| O: -0.88%
H: 4.42%
C: -1.77%
treatment atopic dermatitis dermatitis trial enroll
Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
Published: 2021-10-19 (Crawled : 12:15) - prnewswire.com
IKT | $1.37 -32.84% -47.83% 0
|
Health Technology
|
| O: 4.0%
H: 7.14%
C: 5.49%
phase 1 ikt-148009 parkinson trial phase 1b phase 2b
Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study
Published: 2021-10-19 (Crawled : 12:15) - biospace.com/
EDSA | $4.38 -1.57% 0.22% 0
|
Health Technology
|
| O: 13.82%
H: 0.45%
C: -6.7%
covid biotech iot eb05 covid-19
Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab
Published: 2021-10-19 (Crawled : 12:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.16%
H: 4.62%
C: 4.46%
presentation treatment lenzilumab biomarkers
Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD
Published: 2021-10-19 (Crawled : 11:00) - globenewswire.com
OPT | News | $3.38 2.42% 2.37% 0
|
Health Technology
|
| O: 8.01%
H: 2.05%
C: -4.35%
trials phase 3 trial enroll
Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
Published: 2021-10-18 (Crawled : 00:00) - biospace.com/
ETTX | $2.19 -0.46% 0.46%
|
Health Technology
|
| O: 0.63%
H: 0.66%
C: -1.89%
positive results topline phase 3 trial
Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)
Published: 2021-10-18 (Crawled : 00:00) - biospace.com/
PRTK | $2.23 0.0% 4.8M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -4.4%
disease phase 2 phase 2b bacteria enroll
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
Published: 2021-10-18 (Crawled : 00:00) - biospace.com/
PBYI | $5.17 3.19% 3.09% 1
|
Health Technology
|
| O: -0.17%
H: 0.83%
C: -1.99%
CELC | $17.54 1.74% 1.71% 0
|
Commercial Services
|
| O: 0.55%
H: 1.42%
C: -3.61%
collaboration cancer breast cancer trial train brain metastases
Gainers vs Losers
| 68% | 32% |
Top 10 Gainers
AGBA | $2.615 109.2% 14M
|
Finance
EDBL | News | $7.37 96.01% 650K
|
AZTR 4 | $0.222 13.85% 220K
|
n/a
CANG | $1.5 11.94% 410K
|
Technology Services
CAN | News | $1.03 10.74% 2.4M
|
Electronic Technology
YS | $0.818 10.39% 5.6K
|
n/a
FNCH | $2.52 9.09% 14K
|
Professional, Scientific, and T...
WETH | $2.59 7.92% 34K
|
DXYZ 4 | $26.41 6.97% 50K
|
n/a
ZCMD | $1.7 6.92% 2.2M
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.